NCT03292783View on ClinicalTrials.gov

This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 18, 2017

Primary Completion Date

March 2, 2021

Study Completion Date

March 2, 2021

Conditions
Advanced Solid Tumors
Interventions
DRUG

NOV1501 (ABL001)

VEGF/DLL4 targeting bispecific antibody

Trial Locations (2)

13620

Seoul National University Bundang Hospital, Seongnam-si

135-710

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

ABL Bio, Inc.
All Listed Sponsors
collaborator

National OncoVenture

OTHER

lead

ABL Bio, Inc.

INDUSTRY